Search - tctmd.com

Displaying 321 - 340 of 542

Sort: Relevancy | Date

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

News Daily News

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Michael O'Riordan

July 14, 2020

A secondary analysis from ASPREE sets up two large RCTs testing statins in an elderly primary-prevention population.

News Daily News

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Michael O'Riordan

July 06, 2020

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

June 25, 2020

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

June 08, 2020

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

News Features

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

Michael O'Riordan

May 12, 2020

Stroke ‘Surge’ in the Young Fuels Debate Over COVID-19’s Culpability

News Features

Stroke ‘Surge’ in the Young Fuels Debate Over COVID-19’s Culpability

May 08, 2020

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Inclisiran Data in NEJM Prompt Talk of What Comes Next

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

March 24, 2020

Missed Opportunities: Many HF Patients Not Tested for CAD

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

March 20, 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

News Conference News ACC 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

Yael L. Maxwell

March 19, 2020

News Daily News

COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say

March 17, 2020

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

News Conference News ISC 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

February 27, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.